Market Activity Highlights for Mangoceuticals (MGRX)
Mangoceuticals (MGRX) closed the trading session on Thursday, 22 April 2026, at a price that marked a 7.14 % rise over the previous 24‑hour period. At the close, the share price stood at approximately USD 0.30 on major exchanges. The stock is actively traded, with a total of 22.2 million shares outstanding and a market capitalization of USD 6.2 million. In the last 24 hours alone, roughly USD 53 000 of Mangoceuticals shares changed hands, reflecting a moderate but steady liquidity profile.
Historical Context
- Recent Performance: Over the last month, Mangoceuticals has experienced a decline of 33.48 %, underscoring the volatility that can accompany early‑stage companies in the tele‑medicine space.
- Moving Averages & Price Ranges: The simple moving average for the past 200 days sits at USD 0.43, providing a reference point for investors assessing short‑term trends. The 52‑week high reached USD 2.50 on 24 October 2025, while the 52‑week low dropped to USD 0.16 on 20 March 2026. These figures illustrate the breadth of price swings the stock has endured.
Peer Performance Snapshot (Past 24 Hours)
| Stock | 24‑Hour Change | Current Price | Market Capitalisation |
|---|---|---|---|
| Cycurion (CYCU) | –0.92 % | USD 2.18 | USD 7 million |
| Senti Biosciences I (SNTI) | +0.44 % | USD 0.22 | USD 7.1 million |
| Endra Life Sciences (NDRA) | –5.89 % | USD 4.68 | USD 7.1 million |
| Rain Enhancement Techno (RAIN) | –2.53 % | USD 0.56 | USD 7.4 million |
| Natural Alternatives (NAII) | +0.87 % | USD 1.19 | USD 7 million |
These contemporaneous movements suggest a market environment that is broadly indifferent to sector‑specific catalysts, with most peers hovering around their recent support levels.
Company Overview
Mangoceuticals, Inc. operates as a tele‑medicine service and product provider within the consumer staples sector, headquartered in Dallas, United States. The company delivers wellness‑care services through telehealth platforms and collaborates with licensed pharmacies for online medication fulfillment. Its offerings encompass both consultation services and prescription products, aimed at enhancing patient convenience and access to care.
Founded to bridge the gap between traditional medical practice and digital convenience, Mangoceuticals went public on Nasdaq following an IPO on 17 February 2023. The firm maintains an online presence at www.mangorx.com , where stakeholders can explore its range of services, product lines, and regulatory compliance measures.
Investor Takeaway: While Mangoceuticals has demonstrated a notable 7.14 % gain within a single trading day, the broader context of a month‑long decline and a 200‑day moving average below the current price suggests caution. Potential investors should weigh the company’s strategic position in tele‑health against its historical price volatility and peer performance trends.
